82
FDA rejects ecstasy as a therapy: what’s next for psychedelics? (www.nature.com)
submitted 3 months ago by ArcticDagger@feddit.dk to c/science@lemmy.world
23 comments fedilink hide all child comments

But Marks points out that the FDA typically follows the advice of its independent advisory committees — and the one that evaluated MDMA in June overwhelmingly voted against approving the drug, citing problems with clinical trial design that the advisers felt made it difficult to determine the drug’s safety and efficacy. One concern was about the difficulty of conducting a true placebo-controlled study with a hallucinogen: around 90% of the participants in Lykos’s trials guessed correctly whether they had received the drug or a placebo, and the expectation that MDMA should have an effect might have coloured their perception of whether it treated their symptoms.

Another concern was about Lykos’s strategy of administering the drug alongside psychotherapy. Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), the non-profit organization that created Lykos, has said that he thinks the drug’s effects are inseparable from guided therapy. MDMA is thought to help people with PTSD be more receptive and open to revisiting traumatic events with a therapist. But because the FDA doesn’t regulate psychotherapy, the agency and advisory panel struggled to evaluate this claim. “It was an attempt to fit a square peg into a round hole,” Marks says.

you are viewing a single comment's thread
view the rest of the comments
[-] qaz@lemmy.world 3 points 3 months ago

biochemical effect, placebo = 0

I'm not sure if the biochemical effects of a placebo are 0.

In conditioning, a neutral stimulus saccharin is paired in a drink with an agent that produces an unconditioned response. For example, that agent might be cyclophosphamide, which causes immunosuppression. After learning this pairing, the taste of saccharin by itself is able to cause immunosuppression, as a new conditioned response via neural top-down control. Such conditioning has been found to affect a diverse variety of not just basic physiological processes in the immune system but ones such as serum iron levels, oxidative DNA damage levels, and insulin secretion. Recent reviews have argued that the placebo effect is due to top-down control by the brain for immunity and pain. Pacheco-López and colleagues have raised the possibility of "neocortical-sympathetic-immune axis providing neuroanatomical substrates that might explain the link between placebo/conditioned and placebo/expectation responses". There has also been research aiming to understand underlying neurobiological mechanisms of action in pain relief, immunosuppression, Parkinson's disease and depression.

Shamelessly stolen from Wikipedia because I couldn't find the original source

this post was submitted on 14 Aug 2024
82 points (100.0% liked)

science

14595 readers
118 users here now

A community to post scientific articles, news, and civil discussion.

rule #1: be kind

<--- rules currently under construction, see current pinned post.

2024-11-11

founded 1 year ago
MODERATORS
m3t00@lemmy.world
Joleee@lemmy.world
laverabe@lemmy.world
DeadPand@midwest.social